Literature DB >> 30858642

An Approach to the Pharmacotherapy of Neuroleptic Malignant Syndrome.

Roland van Rensburg1, Eric H Decloedt1.   

Abstract

Neuroleptic malignant syndrome is a rare, idiosyncratic emergency associated with exposure to dopamine antagonists, commonly antipsychotic drugs. The typical clinical picture consists of altered consciousness, muscular rigidity, fever, and autonomic instability. While the condition has generally been well described, the pathophysiology is still poorly understood. The importance of this case report is to highlight the lack of robust evidence-based treatment for this emergency. We submit an approach to the pharmacotherapy of neuroleptic malignant syndrome based on the available evidence.

Entities:  

Keywords:  amantadine; benzodiazepines; bromocriptine; dantrolene; neuroleptic malignant syndrome; pharmacotherapy; severity

Mesh:

Year:  2019        PMID: 30858642      PMCID: PMC6386430     

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  31 in total

Review 1.  Neuroleptic malignant syndrome.

Authors:  P Adnet; P Lestavel; R Krivosic-Horber
Journal:  Br J Anaesth       Date:  2000-07       Impact factor: 9.166

2.  Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome.

Authors:  Kazuo Mihara; Tsuyoshi Kondo; Akihito Suzuki; Norio Yasui-Furukori; Shingo Ono; Akira Sano; Kazuko Koshiro; Koichi Otani; Sunao Kaneko
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2003-02       Impact factor: 3.568

Review 3.  The serotonin syndrome.

Authors:  H Sternbach
Journal:  Am J Psychiatry       Date:  1991-06       Impact factor: 18.112

4.  Development of an animal model for neuroleptic malignant syndrome: heat-exposed rabbits with haloperidol and atropine administration exhibit increased muscle activity, hyperthermia, and high serum creatine phosphokinase level.

Authors:  H Tanii; N Taniguchi; H Niigawa; T Hosono; Y Ikura; S Sakamoto; T Kudo; T Nishimura; M Takeda
Journal:  Brain Res       Date:  1996-12-16       Impact factor: 3.252

5.  An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method.

Authors:  Ronald J Gurrera; Stanley N Caroff; Abigail Cohen; Brendan T Carroll; Francis DeRoos; Andrew Francis; Steven Frucht; Sanjay Gupta; James L Levenson; Ahsan Mahmood; Stephan C Mann; Michael A Policastro; Patricia I Rosebush; Henry Rosenberg; Perminder S Sachdev; Julian N Trollor; Varadaraj R Velamoor; Charles B Watson; Jayne R Wilkinson
Journal:  J Clin Psychiatry       Date:  2011-06-28       Impact factor: 4.384

Review 6.  Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases.

Authors:  J N Trollor; P S Sachdev
Journal:  Aust N Z J Psychiatry       Date:  1999-10       Impact factor: 5.744

Review 7.  Clinical management of neuroleptic malignant syndrome.

Authors:  V L Susman
Journal:  Psychiatr Q       Date:  2001

Review 8.  Neuroleptic malignant syndrome.

Authors:  S N Caroff; S C Mann
Journal:  Med Clin North Am       Date:  1993-01       Impact factor: 5.456

9.  Chlorpromazine-induced neuroleptic malignant syndrome and its response to diazepam.

Authors:  T Y Lew; G Tollefson
Journal:  Biol Psychiatry       Date:  1983-12       Impact factor: 13.382

Review 10.  Neuroleptic Malignant Syndrome.

Authors:  Dominic J Pileggi; Aaron M Cook
Journal:  Ann Pharmacother       Date:  2016-07-19       Impact factor: 3.154

View more
  2 in total

1.  Neuroleptic Malignant Syndrome: Early Diagnosis Saves Lives in Low-Resource Settings.

Authors:  Micheal Kiyingi; Felix Bongomin; Mark Kizito; Mark Kaddumukasa
Journal:  Int Med Case Rep J       Date:  2020-08-24

2.  Malignant Catatonia Versus Neuroleptic Malignant Syndrome.

Authors:  Saral Desai; Tinu Hirachan; Anca Toma; Adela Gerolemou
Journal:  Cureus       Date:  2021-06-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.